Sugi Predict

Sugi Predict / Targets / DUSP6

DUSP6

Dual specificity protein phosphatase 6 · Q16828 · DUSP6 on Sugi Atlas →

826 patent compounds predicted against DUSP6, 739 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17980328 SCHEMBL17980328 1.00 3/20
SCHEMBL17980329 SCHEMBL17980329 1.00 3/20
SCHEMBL4669021 SCHEMBL4669021 0.83 3/20
SCHEMBL4669023 SCHEMBL4669023 0.83 3/20
SCHEMBL2397608 SCHEMBL2397608 0.91 2/20
SCHEMBL2398377 SCHEMBL2398377 0.91 2/20
SCHEMBL12267452 SCHEMBL12267452 0.81 2/20
SCHEMBL4670417 SCHEMBL4670417 0.69 2/20
SCHEMBL4670420 SCHEMBL4670420 0.69 2/20
SCHEMBL13855916 SCHEMBL13855916 0.69 2/20
SCHEMBL4668189 SCHEMBL4668189 0.68 2/20
SCHEMBL4668190 SCHEMBL4668190 0.68 2/20
SCHEMBL13855965 SCHEMBL13855965 0.68 2/20
SCHEMBL4669151 SCHEMBL4669151 0.68 2/20
SCHEMBL4669154 SCHEMBL4669154 0.68 2/20
SCHEMBL13855954 SCHEMBL13855954 0.67 2/20
SCHEMBL13855934 SCHEMBL13855934 0.66 2/20
SCHEMBL13855929 SCHEMBL13855929 0.66 2/20
SCHEMBL13855923 SCHEMBL13855923 0.65 2/20
SCHEMBL4669384 SCHEMBL4669384 0.65 2/20

Clinical trials — most relevant to DUSP6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans PHASE4COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Implementing Patients´ Competence in Oral Breast Cancer Therapy nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Cancer Fusion Hybrids and Desmoplasia nanUNKNOWN
RASopathy Biorepository nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP6 binder may also engage these)

ProteinNameSimilarity
Q2KJ36 — 1.000 Q2KJ36 →
Q9DBB1 — 1.000 Q9DBB1 →
Q64346 — 1.000 Q64346 →
P28563 — 0.993 P28563 →
Q64623 — 0.991 Q64623 →
Q9VVW5 — 0.990 Q9VVW5 →
Q90W58 — 0.990 Q90W58 →
Q62767 — 0.989 Q62767 →
Q63340 — 0.989 Q63340 →
Q91Z46 — 0.988 Q91Z46 →
DUSP4 Dual specificity protein phosphatase 4 0.988 landscape →
Q91790 — 0.988 Q91790 →
Q16829 — 0.987 Q16829 →
Q8BFV3 — 0.985 Q8BFV3 →
Q0IID7 — 0.985 Q0IID7 →
DUSP10 Dual specificity protein phosphatase 10 0.983 landscape →
Q9ESS0 — 0.982 Q9ESS0 →
Q9PW71 — 0.980 Q9PW71 →
DUSP1 Dual specificity protein phosphatase 1 0.979 landscape →
Q9JIM4 — 0.978 Q9JIM4 →
P0C598 — 0.976 P0C598 →
O54838 — 0.976 O54838 →
P0C5A0 — 0.976 P0C5A0 →
P0C593 — 0.976 P0C593 →
P0C599 — 0.975 P0C599 →
Q99N11 — 0.975 Q99N11 →
Q9D0T2 — 0.974 Q9D0T2 →
PTPN3 Tyrosine-protein phosphatase non-receptor type 3 0.974 landscape →
Q95K79 — 0.973 Q95K79 →
V6CIV8 — 0.973 V6CIV8 →